Abbott Laboratories
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Ford
- Full Time Employees
- 114,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Abbott Park Road Abbott Park IL United States of America 60064-6400
- IPO Date
- Mar 17, 1980
- CIK
- 0000001800
- Website
- abbott.com
- Similar Companies
- Business
- Abbott Laboratories (NYSE: ABT) develops, manufactures, and sells a broad range of health care products worldwide. The company operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices; its core offerings include branded generic pharmaceuticals such as Branded generics in emerging markets, anti-infectives, and gastrointestinal drugs; diagnostics encompassing point-of-care testing systems like i-STAT, molecular diagnostics via Alinity platforms, rapid diagnostics under BinaxNOW and Determine brands, and core laboratory instruments; nutritional products including pediatric formulas like Similac and Pediasure, adult nutritionals such as Ensure and Glucerna, and medical foods; as well as medical devices featuring cardiovascular and neuromodulation devices including FreeStyle Libre continuous glucose monitoring systems, Aveir leadless pacemakers, TactiFlex ablation catheters, and structural heart devices like Amplatzer occluders. Abbott serves health care professionals, consumers, hospitals, laboratories, and governments across more than 100 countries, with principal manufacturing facilities in the United States, Europe, Asia, and Latin America. Founded in 1888 and headquartered in Abbott Park, Illinois, the company maintains a diversified portfolio without notable subsidiaries or parent relationships impacting its core structure. In recent developments within the last two years, Abbott completed the acquisition of Cardiovascular Systems, Inc. in 2024 to expand its cardiovascular portfolio; launched the FreeStyle Libre 3 integrated continuous glucose monitoring sensor in multiple markets including the U.S.; introduced the AVEIR DR dual chamber leadless pacemaker system and the TactiFlex Sensor Enabled Ablation Catheter; formed strategic partnerships for digital health integrations and expanded diagnostics manufacturing capacity amid global demand surges; and reported strong growth in its diabetes and cardiovascular segments during 2025 earnings.
Abbott (ABT) Stock Declines While Market Improves: Some Information for Investors
Abbott declares 410th consecutive quarterly dividend
Abbott declares 410th consecutive quarterly dividend
Abbott Laboratories Remains Structurally Undervalued
Abbott (ABT) Dips More Than Broader Market: What You Should Know
Mounting Evidence Backs Abbott's Cancer Diagnostics Growth Story
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around
New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
Baron Discovery Fund Q1 2026: Who Moved The Needle
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
Abbott Labs must face lawsuit over PediaSure children's growth claims
Abbott Addresses a Major Diabetes Care Gap With Tech Innovation
ABT DCF Analysis: Intrinsic Value $93 vs Price $88
3 Beaten-Down Stocks to Buy and Hold Forever
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock
BSX vs. ABT: Which Medical Stock Has More Upside Potential?
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?